Literature DB >> 26631401

Management of iatrogenic crystalline lens injury occurred during intravitreal injection.

Gurkan Erdogan1, Betul Onal Gunay2, Cihan Unlu1, Murat Gunay3, Ahmet Ergin1.   

Abstract

To evaluate the approach to management of iatrogenic crystalline lens injury occurred during intravitreal injection (IVI). The patients who were managed operatively or followed-up without intervention after the iatrogenic lens injury due to IVI were included in the study. Capsular breaks remained either quiescent or resulted in cataract formation in the patients with inadvertent crystalline lens capsule damage. Phacoemulsification surgery was performed in patients with cataract formation with lower fluidic settings. A total of 9 cases included in the study. Seven cases underwent phacoemulsification with intraocular lens implantation. Two cases remained as quiescent lens injury during the follow-up. In 2 cases, dislocation of lens fragments occurred during phacoemulsification where pars plana vitrectomy was performed at the same session. After iatrogenic crystalline lens injury, capsular damage could remain quiescent or progress to cataract formation. Although phacoemulsification surgery can be performed with appropriate parameters, lens fragment dislocation can be observed in cases with traumatic lens damage secondary to IVI.

Entities:  

Keywords:  Iatrogenic lens injury; Intravitreal injection; Quiescent lens injury; Surgery

Mesh:

Substances:

Year:  2015        PMID: 26631401     DOI: 10.1007/s10792-015-0156-5

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  8 in total

1.  Incidence of damage to the crystalline lens during intravitreal injections.

Authors:  Carsten H Meyer; Eduardo B Rodrigues; Stephan Michels; Stefan Mennel; Jörg C Schmidt; Hans-Martin Helb; Annette Hager; Mauricio Martinazzo; Michel E Farah
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

2.  Complications in patients after intravitreal injection of bevacizumab.

Authors:  Chiharu Shima; Hirokazu Sakaguchi; Fumi Gomi; Motohiro Kamei; Yasushi Ikuno; Yusuke Oshima; Miki Sawa; Motokazu Tsujikawa; Shunji Kusaka; Yasuo Tano
Journal:  Acta Ophthalmol       Date:  2007-11-17       Impact factor: 3.761

3.  Management of cataract caused by inadvertent capsule penetration during intravitreal injection of ranibizumab.

Authors:  Muhammad Usman Saeed; Som Prasad
Journal:  J Cataract Refract Surg       Date:  2009-11       Impact factor: 3.351

4.  Quiescent posterior capsule trauma after intravitreal injection: implications for the cataract surgeon.

Authors:  Yousuf M Khalifa; Seth M Pantanelli
Journal:  J Cataract Refract Surg       Date:  2011-07       Impact factor: 3.351

5.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

6.  Pegaptanib for neovascular age-related macular degeneration.

Authors:  Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

7.  Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections.

Authors:  Ioannis D Ladas; Dimitrios A Karagiannis; Alexandros A Rouvas; Athanasios I Kotsolis; Andromachi Liotsou; Ioannis Vergados
Journal:  Retina       Date:  2009-03       Impact factor: 4.256

8.  Short-term complications of intravitreal injections of triamcinolone and bevacizumab.

Authors:  J B Jonas; U H Spandau; F Schlichtenbrede
Journal:  Eye (Lond)       Date:  2008-02-22       Impact factor: 3.775

  8 in total
  2 in total

1.  Occurrence of intraocular air bubbles during intravitreal injections for retinopathy of prematurity.

Authors:  Emine Alyamac Sukgen; Murat Gunay; Yusuf Kocluk
Journal:  Int Ophthalmol       Date:  2016-05-23       Impact factor: 2.031

2.  Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial.

Authors:  Stephen R Russell; Arlene V Drack; Artur V Cideciyan; Samuel G Jacobson; Bart P Leroy; Caroline Van Cauwenbergh; Allen C Ho; Alina V Dumitrescu; Ian C Han; Mitchell Martin; Wanda L Pfeifer; Elliott H Sohn; Jean Walshire; Alexandra V Garafalo; Arun K Krishnan; Christian A Powers; Alexander Sumaroka; Alejandro J Roman; Eva Vanhonsebrouck; Eltanara Jones; Fanny Nerinckx; Julie De Zaeytijd; Rob W J Collin; Carel Hoyng; Peter Adamson; Michael E Cheetham; Michael R Schwartz; Wilhelmina den Hollander; Friedrich Asmus; Gerard Platenburg; David Rodman; Aniz Girach
Journal:  Nat Med       Date:  2022-04-04       Impact factor: 87.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.